← All stocks

NovaBridge Biosciences

NBP Net buying

CIK 0001778016 #3889 in the set updated 17 Sep 2026

Bought (12 mo)

$577.30K

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$148.44K

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$148.44K

6 of 6 sales

Net

+$428.86K

+$428.86K against sales at will

By person

5 insiders · 7 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Hagler Mark Arnold

Chief Commercial Officer

$577.30K (1)

—

+$577.30K

230,000

0.0867%

$170.20K

—

Cao Sean Wuxiong

Chief Bus. Development Officer

—

$122.49K (2)

−$122.49K

266,467

0.1004%

$197.19K

+371.9%

Xu Cong Claire

EVP, Clinical Development

—

$20.35K (3)

−$20.35K

304,201

0.1146%

$225.11K

+7.0%

Dennis Phillip Andrew

Chief Medical Officer

—

$5.61K (1)

−$5.61K

157,941

0.0595%

$116.88K

+10.6%

Lenz Robert A.

Director

—

17,218

0.0065%

$12.74K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Cao Sean Wuxiong

9 Sep 2026

Chief Bus. Development Officer

Sell

107,978

$0.74

$79.90K

Xu Cong Claire

31 Aug 2026

EVP, Clinical Development

Sell

3,282

$0.79

$2.59K

Xu Cong Claire

6 Jul 2026

SVP, Clinical Development

Sell

4,485

$0.89

$3.99K

Dennis Phillip Andrew

18 Jun 2026

Chief Medical Officer

Sell

8,494

$0.66

$5.61K

Xu Cong Claire

1 Jun 2026

SVP, Clinical Development

Sell

3,494

$3.94

$13.77K

Cao Sean Wuxiong

14 May 2026

See Remarks

Sell

21,399

$1.99

$42.58K

Hagler Mark Arnold

24 Apr 2026

See Remarks

Buy

230,000

$2.51

$577.30K

What was left out

Form 4 filings counted 14

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 6

Transactions with no price 0

Shares from compensation/vesting 411,481

History held since 28 Apr 2026